PMC:7554011 / 24663-25115 JSONTXT

{"project":"2_test","denotations":[{"id":"33051713-16707408-26811","span":{"begin":191,"end":193},"obj":"16707408"},{"id":"33051713-18296556-26812","span":{"begin":194,"end":196},"obj":"18296556"},{"id":"33051713-15102869-26813","span":{"begin":197,"end":199},"obj":"15102869"},{"id":"33051713-18296556-26814","span":{"begin":448,"end":450},"obj":"18296556"}],"text":"PK parameters of montelukast (Cmax and AUC0–24 h) after the administration of the 4 mg dose to infants of 1 to 3 months were higher and more variable than for older infants (3 to 24 months) (16,17,19). The higher systemic exposure in the younger subgroup when given the dose of montelukast was attributed to their smaller body weight, and to the levels of CYP3A4, which are only about 30 to 40% of adult levels in ages younger than 3 to 12 months (17)."}